journal article·2023-06

Ablation of Gap Junction Protein Improves the Efficiency of Nanozyme‐Mediated Catalytic/Starvation/Mild‐Temperature Photothermal Therapy

Yongjuan Li, Yu Zhang, Ya Dong, Ozioma Udochukwu Akakuru, Xiaohan Yao, Jinmeng Yi, Xinyan Li, Linlin Wang, Xiaohan Lou, Baoyu Zhu, Kelong Fan, Zhihai Qin

Advanced Materials· Volume 35· Issue 22
Publisher page

Abstract

Abstract Reactive oxygen species (ROS)‐mediated tumor catalytic therapy is typically hindered by gap junction proteins that form cell‐to‐cell channels to remove cytotoxic ROS, thereby protecting tumor cells from oxidative damage. In this work, a multifunctional nanozyme, FePGOGA, is designed and prepared by Fe(III)‐mediated oxidative polymerization (FeP), followed by glucose oxidase (GOx) and GAP19 peptides co‐loading through electrostatic and π–π interactions. The FePGOGA nanozyme exhibits excellent cascade peroxidase‐ and glutathione‐oxidase‐like activities that efficiently catalyze hydrogen peroxide conversion to hydroxyl radicals and convert reduced glutathione to oxidized glutathione disulfide. The loaded GOx starves the tumors and aggravates tumor oxidative stress through glucose decomposition, while GAP19 peptides block the hemichannels by inducing degradation of Cx43, thus increasing the accumulation of intracellular ROS, and decreasing the transport of intracellular glucose. Furthermore, the ROS reacts with primary amines of heat shock proteins to destroy their structure and function, enabling tumor photothermal therapy at the widely sought‐after mild temperature (mildPTT, ≤45 °C). In vivo experiments demonstrate the significant antitumor effectof FePGOGA on cal27 xenograft tumors under near‐infrared light irradiation. This study demonstrates the successful ablation of gap junction proteins to overcome resistance to ROS‐mediated therapy, providing a regulator to suppress tumor self‐preservation during tumor starvation, catalytic therapy, and mildPTT.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Extracellular vesicles in disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Medical Research Center The First Affiliated Hospital of Zhengzhou University Zhengzhou University Zhengzhou Henan 450001 China

Center of Infection and Immunity Academy of Medical Sciences Zhengzhou University Zhengzhou Henan 450001 China

Department of Stomatology The First Affiliated Hospital of Zhengzhou University Zhengzhou University Zhengzhou Henan 450001 China

Department of Chemical and Petroleum Engineering Schulich School of Engineering University of Calgary Calgary Alberta T2N 1N4 Canada

Nanozyme Medical Center School of Basic Medical Sciences Zhengzhou University Zhengzhou Henan 450001 China

CAS Engineering Laboratory for Nanozyme Key Laboratory of Protein and Peptide Pharmaceutical Institute of Biophysics Chinese Academy of Sciences 15 Datun Road Beijing 100101 China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · Youth Innovation Promotion Association of the Chinese Academy of Sciences

References (76)

Show source-provided references
1. 10.1186/s12943-022-01530-y10.1186/s12943-022-01530-y ↗
2. 10.1186/s12943-019-1089-910.1186/s12943-019-1089-9 ↗
3. 10.1038/s41392-021-00648-710.1038/s41392-021-00648-7 ↗
4. 10.1016/j.trecan.2019.02.00310.1016/j.trecan.2019.02.003 ↗
5. 10.1038/s41416-021-01564-x10.1038/s41416-021-01564-x ↗
6. 10.1038/s41573-022-00493-510.1038/s41573-022-00493-5 ↗
7. 10.1016/j.cmet.2019.06.00110.1016/j.cmet.2019.06.001 ↗
8. 10.1158/0008-5472.CAN-18-396210.1158/0008-5472.CAN-18-3962 ↗
9. 10.1016/j.molcel.2020.05.03410.1016/j.molcel.2020.05.034 ↗
10. 10.1039/C7CS00471K10.1039/C7CS00471K ↗
11. 10.1002/adhm.20220160710.1002/adhm.202201607 ↗
12. 10.1038/s41571-020-0410-210.1038/s41571-020-0410-2 ↗
13. 10.1016/j.jconrel.2020.06.03210.1016/j.jconrel.2020.06.032 ↗
14. 10.1021/acssensors.2c0146810.1021/acssensors.2c01468 ↗
15. 10.1002/adhm.20190105810.1002/adhm.201901058 ↗
16. 10.1124/pharmrev.120.00005310.1124/pharmrev.120.000053 ↗
17. 10.1016/j.addr.2022.11426910.1016/j.addr.2022.114269 ↗
18. 10.1002/smll.20220340010.1002/smll.202203400 ↗
19. Chen J. · Small · 2022 · 16
20. 10.1016/j.biomaterials.2021.12111010.1016/j.biomaterials.2021.121110 ↗
21. 10.1038/s12276-020-0384-210.1038/s12276-020-0384-2 ↗
22. 10.1002/anie.20180566410.1002/anie.201805664 ↗
23. 10.1002/smll.20210386810.1002/smll.202103868 ↗
24. 10.1002/anie.20171202710.1002/anie.201712027 ↗
25. 10.1002/adma.20180832510.1002/adma.201808325 ↗
26. 10.1002/adma.20220473310.1002/adma.202204733 ↗
27. 10.1021/acsami.9b0001010.1021/acsami.9b00010 ↗
28. 10.1039/C7CS00891K10.1039/C7CS00891K ↗
29. 10.1002/advs.20210146710.1002/advs.202101467 ↗
30. 10.1016/j.cmet.2022.10.01210.1016/j.cmet.2022.10.012 ↗
31. 10.1093/neuonc/nox20710.1093/neuonc/nox207 ↗
32. 10.1073/pnas.180390711510.1073/pnas.1803907115 ↗
33. 10.1016/j.canlet.2018.10.04310.1016/j.canlet.2018.10.043 ↗
34. 10.1016/j.tcb.2019.07.00110.1016/j.tcb.2019.07.001 ↗
35. 10.1038/s41419-022-05089-w10.1038/s41419-022-05089-w ↗
36. 10.1021/acsami.2c0586910.1021/acsami.2c05869 ↗
37. 10.1002/smll.20210610010.1002/smll.202106100 ↗
38. 10.1016/j.jconrel.2021.07.04010.1016/j.jconrel.2021.07.040 ↗
39. 10.1161/CIRCRESAHA.119.31650210.1161/CIRCRESAHA.119.316502 ↗
40. 10.1073/pnas.210739111910.1073/pnas.2107391119 ↗
41. 10.1172/JCI13775210.1172/JCI137752 ↗
42. 10.3390/ijms2310557510.3390/ijms23105575 ↗
43. 10.3390/cancers1103030110.3390/cancers11030301 ↗
44. 10.1038/s41419-020-2392-510.1038/s41419-020-2392-5 ↗
45. 10.1038/s41374-021-00675-610.1038/s41374-021-00675-6 ↗
46. 10.1002/adma.20220013910.1002/adma.202200139 ↗
47. 10.1002/adma.20210059510.1002/adma.202100595 ↗
48. 10.1002/adma.20190082210.1002/adma.201900822 ↗
49. 10.3390/cancers1420504310.3390/cancers14205043 ↗
50. 10.1016/j.ijbiomac.2022.01.08510.1016/j.ijbiomac.2022.01.085 ↗
51. 10.1016/j.matdes.2022.11048110.1016/j.matdes.2022.110481 ↗
52. 10.1016/j.cej.2021.13221310.1016/j.cej.2021.132213 ↗
53. 10.1016/j.msec.2021.11248810.1016/j.msec.2021.112488 ↗
54. 10.1016/j.ijbiomac.2021.09.16810.1016/j.ijbiomac.2021.09.168 ↗
55. 10.1016/j.msec.2021.11198010.1016/j.msec.2021.111980 ↗
56. 10.1021/acsami.0c2094010.1021/acsami.0c20940 ↗
57. 10.1021/acsami.0c1716910.1021/acsami.0c17169 ↗
58. 10.1016/j.ijbiomac.2020.10.09110.1016/j.ijbiomac.2020.10.091 ↗
59. 10.1016/j.actbio.2019.06.05310.1016/j.actbio.2019.06.053 ↗
60. 10.2147/IJN.S16329910.2147/IJN.S163299 ↗
61. 10.3390/molecules2306125610.3390/molecules23061256 ↗
62. 10.1002/adhm.20170018110.1002/adhm.201700181 ↗
63. 10.34133/2021/981659410.34133/2021/9816594 ↗
64. 10.1016/j.mtbio.2022.10035310.1016/j.mtbio.2022.100353 ↗
65. 10.1021/acsnano.0c0091010.1021/acsnano.0c00910 ↗
66. 10.1073/pnas.221517012010.1073/pnas.2215170120 ↗
67. 10.7150/thno.6378810.7150/thno.63788 ↗
68. 10.1016/j.biomaterials.2022.12168210.1016/j.biomaterials.2022.121682 ↗
69. 10.1002/adhm.20200043210.1002/adhm.202000432 ↗
70. 10.1002/adma.20220685110.1002/adma.202206851 ↗
71. 10.1016/j.actbio.2022.12.04910.1016/j.actbio.2022.12.049 ↗
72. 10.1021/acsami.1c0100610.1021/acsami.1c01006 ↗
73. 10.1021/acsami.0c1521110.1021/acsami.0c15211 ↗
74. 10.1002/advs.20200122310.1002/advs.202001223 ↗
75. 10.3390/ijms2119734010.3390/ijms21197340 ↗
76. 10.3389/fncel.2018.0037210.3389/fncel.2018.00372 ↗